Endoprosthesis with Selective Thrombogenic Element Deployment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing stent technologies fail to effectively prevent the continued growth of aneurysms as they can be irrigated by blood vessels other than the targeted artery, posing a risk of rupture, and the introduction of thrombogenic materials is complicated and risky.
Innovation Solution
A stent with thrombogenic elements arranged on its outer surface and selectively deactivatable retaining elements that deploy away from the stent after deployment, ensuring uniform distribution around the aneurysm without obstructing the stent's placement or entering the blood flow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombogenic materials are introduced into the aneurysm to prevent rupture, then the risk of aneurysm rupture is reduced, but the procedure becomes complicated and risky with potential obstruction of stent fitting
Solution Approach 1:
The patent combines the stent and thrombogenic elements into a single integrated endoprosthesis device. The thrombogenic elements are built onto the stent structure during manufacturing, eliminating the need for separate introduction procedures. This merging of functions directly reduces procedure complexity while maintaining aneurysm rupture prevention capability.
Solution Approach 2:
The thrombogenic elements are pre-positioned on the stent during manufacturing before the device is implanted. This preliminary placement ensures that the thrombogenic materials are already in position to prevent aneurysm rupture without requiring additional procedural steps, thereby simplifying the overall intervention while maintaining reliability.
2Reliability
If thrombogenic materials are placed on the stent surface, then aneurysm growth is prevented, but the materials may obstruct stent fitting or penetrate the inner conduit
Solution Approach 1:
The patent applies thrombogenic elements selectively to specific regions of the stent outer surface where they are most effective for preventing aneurysm growth, rather than uniformly across the entire stent. This localized application ensures thrombogenic materials are positioned to prevent aneurysm expansion while avoiding obstruction of the stent lumen during fitting, thereby maintaining ease of operation.
Solution Approach 2:
The thrombogenic elements are designed with controlled mobility relative to the stent surface. They can move or deploy after implantation to ensure optimal positioning for thrombosis prevention, while being constrained during the fitting process to avoid obstruction. This dynamic behavior allows the system to adapt to different operational phases, maintaining both reliability and ease of operation.
3Reliability
If thrombogenic elements are made movable away from the stent surface, then they can effectively promote thrombosis, but they may obstruct blood flow or enter the blood flow
Solution Approach 1:
The patent positions thrombogenic elements specifically on the outer surface of the stent facing the aneurysm sac, where they can effectively promote thrombosis. This localized placement ensures that thrombogenic activity is concentrated where needed for aneurysm treatment while avoiding interference with blood flow through the stent lumen, thereby maintaining reliable thrombosis promotion without harmful effects on blood flow.
Data Source
Figure 1~4
Figure 5~6
Figure 7~8
AI summary
The invention relates to an endoprosthesis (1), in particular a vascular or cardiac endoprosthesis (1), having a body (2) and also one or more thrombogenic elements (3) that are fixed to the endoprosthesis (1) and that are able to extend a distance away from the body outside the latter. The endoprothesis comprises means (33) for selectively retaining the thrombogenic elements near the body (2). The release of the one or more thrombogenic elements, after the endoprosthesis has been fitted in place by a conventional method via a sheath, promotes thrombosis.